Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06247410
Other study ID # 1402rot20ct
Secondary ID 2021-000867-65
Status Completed
Phase Phase 2
First received
Last updated
Start date August 23, 2021
Est. completion date October 30, 2021

Study information

Verified date April 2024
Source SocraTec R&D GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigational medicinal product (IMP) to be tested in the clinical trial (Rotigotine (ROT)-Transdermal System (TDS) (8 mg/24 h)), which is subject to this submission, was designed as a generic of Neupro® 8 mg/24 h, which is marketed in the European Union since 2006 (date of first authorisation is 2006, date of renewal of the authorisation is 2016) and serves as Reference product. It is the intention of this clinical trial to assess patch adhesion properties of the newly developed rotigotine patch and the marketed Reference product Neupro® 8 mg/24 h after multiple patch applications.


Description:

This multi-centre, open, randomized (order of treatments), multiple dose trial will be performed in a 4-period, 2-sequence-crossover design. A washout phase is not needed, i.e. the IMP application of the 2nd study period may take place the day of the IMP removal of the 1st study period (direct switch-over) and so forth. Patients with a diagnosis of idiopathic Parkinson's disease and a continuous and stable dose of rotigotine (at least 8 mg/24 h) including use of an 8 mg/24 hours patch will be randomized. In each of the 4 periods 1 patch, either of Test or Reference will be applied, with a release rate of 8 mg/24 h rotigotine each. Each patch will remain applied for 24 h. Assessment of patch adhesion will be performed 5 min after application of each patch as well as at the end of the application interval prior to removal of the patch. The clinical trial will be performed as a crossover investigation with intra-individual comparison, thus reducing variability of the patch adhesion parameters, which is supposed to be higher between patients than within an individual patient. The patients will continue their usual medications and will only replace one 8 mg/24 h rotigotine containing patch per day with the IMPs for the duration of treatment in the clinical trial. In case of prescribed doses above 8 mg/24 h rotigotine, the remaining dose will be provided by Non-Investigational Medicinal Pproducts (NIMPs). Thus, no interruption in the prescribed dose of rotigotine will occur.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date October 30, 2021
Est. primary completion date October 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. ethnic origin: Caucasian 2. age: 18 years or older 3. diagnosis of idiopathic Parkinson's disease 4. administration of a stable dose of at least 8 mg/24 h rotigotine including use of an 8 mg/24 h patch for at least 2 weeks prior to enrolment 5. agreement to refrain from swimming, bathing or using a sauna on the assessment days 6. written informed consent obtained, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the patients participating in the clinical trial Exclusion Criteria: Safety concerns 1. existing and/or history of significant skin hypersensitivity to adhesives or other transdermal products 2. existing and/or history of dermatitis (eczema; excluding seborrheic skin by Parkinson's disease) 3. existing and/or history of psoriasis 4. existing and/or history of an active skin disease which interferes with the rotigotine patch application according to the investigator's assessment 5. history of or current drug or alcohol dependence 6. existing medical condition or psychiatric condition which, in the opinion of the investigator, could jeopardize or compromise the patient's well-being or ability to participate in this study 7. lifetime history of suicide attempt 8. suicidal ideation in the past 6 months 9. administration of any investigational medicinal product during the last 2 months prior to individual enrolment of the patient 10. diagnosis of COVID-19 within the last 14 days prior to individual enrolment of the patient 11. contact to persons in foreign risk regions as defined by the Robert Koch Institute within the last 14 days prior to individual enrolment of the patient 12. known direct contact with insufficient protection to persons with diagnosis of COVID-19 within the last 14 days prior to individual enrolment upon reporting of the patient For female patients with childbearing potential only: 13. positive pregnancy test at screening examination 14. pregnant or lactating women 15. female patients who do not agree to apply highly effective contraceptive methods Administrative reasons 16. patients suspected or known not to follow instructions 17. patients who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rotigotine 8Mg/24Hrs Patch
Once daily patch application of one Rotigotine 8Mg/24Hrs Patch (Test or Reference) over 4 days

Locations

Country Name City State
Germany Neuroakademie Alzenau GbR Alzenau In Unterfranken Bayern
Germany Neurologisches Fachkrankenhaus für Bewegungsstörungen/ Parkinson Beelitz-Heilstätten Brandenburg
Germany Praxis für Neurologie Dr. med. Christian Oehlwein Gera Thüringen
Germany Curiositas ad Sanum Studien- und Beratungs GmbH Innklinikum Haag i.OB Haag In Oberbayern Bayern
Germany Gertrudis-Klinik Parkinson-Zentrum GmbH Leun Hessen
Germany Curiositas ad Sanum Studien- und Beratungs GmbH München Bayern
Germany Universitätsklinikum Ulm Neur. Studienzentrale im RKU Ulm Baden-Württemberg
Germany Parkinson-Klinik Ortenau GmbH & Co. KG Wolfach Baden-Württemberg

Sponsors (3)

Lead Sponsor Collaborator
SocraTec R&D GmbH Luye Pharma Group Ltd., SocraMetrics GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of patch adhesion properties of the Test product in patients diagnosed with idiopathic Parkinson's disease at the end of the dosing interval Patch adhesion will be assessed for Test/ Reference 5 min and 23 h 55 min after patch application by trained observers. Area(s) detached will be drawn on transparent films of identical size and shape as the patch in question by the trained observer. As suggested by the Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1), June 2015, patch adhesion will be measured by means of the percentage of area that remains adhered at the end of the dosing interval. Additionally, the patch adhesion will be documented by taking photos at the time point of intended patch adhesion assessment of the patch and surrounding area.
The following scores and affiliated percentages for the relative area still in tight contact with the skin will be used in order to quantify the patch adhesion:
0 = = 90% adhered
= = 80% adhered
= = 70% adhered
= = 60% adhered
= = 50% adhered
= < 50% adhered or patch completely off the skin.
24 hours
Primary Comparative assessment of patch adhesion properties of the Test vs. Reference product in patients diagnosed with idiopathic Parkinson's disease at the end of the dosing interval Patch adhesion will be assessed for Test/ Reference 5 min and 23 h 55 min after patch application by trained observers. Area(s) detached will be drawn on transparent films of identical size and shape as the patch in question by the trained observer. As suggested by the Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1), June 2015, patch adhesion will be measured by means of the percentage of area that remains adhered at the end of the dosing interval. Additionally, the patch adhesion will be documented by taking photos at the time point of intended patch adhesion assessment of the patch and surrounding area.
The following scores and affiliated percentages for the relative area still in tight contact with the skin will be used in order to quantify the patch adhesion:
0 = = 90% adhered
= = 80% adhered
= = 70% adhered
= = 60% adhered
= = 50% adhered
= < 50% adhered or patch completely off the skin.
24 hours
Secondary Skin tolerability of Test and Reference based on standardised assessment of Adverse Events of Special Interest Skin irritation will be assessed for Test/ Reference 30 min after patch removal by trained observers. Skin will be visually checked and palpated. The investigator will decide based on own experience or given specifications, if a skin irritation is to be classified as Adverse Event. Additionally, photos of the skin area will be taken for documentation at all assessment time points. The following symptoms and severity grades will be used for assessment of tolerability at the site:
Dermal response: symptom (severity); erythema (none/ minimal/ mild/ moderate/ severe); papules (none/ discrete/ pronounced); oedema (none/ minimal/ definite); vesicles (none/ non-confluent = 5 mm/ confluent/ non-confluent = 5 mm) Skin reaction spreading beyond site Other effects: none; slightly glazed appearance; markedly glazed appearance; glazing with peeling and cracking; glazing with fissures; film of dried serous exudates covering all or part of the site; small petechial erosions and/or scabs
24 hours
Secondary Descriptive characterisation of safety and tolerability of the investigational medicinal products (IMPs) in the trial population Adverse Events (AEs) observed, mentioned upon general questioning, or spontaneously reported will be documented. Adverse Events of Special Interest (AESI): Skin irritation and sensitization symptoms at patch application site Adverse Events will be listed and evaluated descriptively with regard to action taken, frequency, seriousness, intensity, relationship to the IMP, and outcome, as well as period and treatment.
Safety parameters vital signs (BP, pulse rate (PR)): Systolic and diastolic arterial blood pressure will be measured by oscillometry using an automatic non-invasive device.
Abnormal findings during this safety measurements, assessed as clinically relevant by the investigator, will be reported as adverse events and will be followed up and/or treated as medically appropriate.
4 days
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A